The product of the Epstein-Barr virus BZLF1 gene encodes a protein which is related to c-fos, it has been shown to bind specifically to a consensus AP-1 site, and its expression in latently Epstein-Barr virus-infected lymphocytes is sufficient to trigger the viral lytic cycle. We identified several elements within the BZLF1 promoter (Zp) which are responsive to the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), an inducer of the viral lytic cycle. These elements fall into two classes based on the factors which bind to these sequences and their resulting functional behavior. Four of the elements are homologous (ZI elements) and share homology to a protein-binding domain in the promoter region of the coordinately expressed BRLF1 gene. When cloned upstream of heterologous promoters, the ZI elements function as silencers which exhibit TPA-inducible enhancer activity. A distinct TPA-responsive element (ZII) is located near the TATA box and shares homology with the AP-l-binding site in the c-jun promoter. A synthetic oligonucleotide with a sequence corresponding to the ZII element effectively competes for binding of nuclear factors to the c-jun AP-1 site. Furthermore, we found that a complex of c-jun and c-fos bound to the ZII domain.
Epstein-Barr virus (EBV) is a lymphotropic human herpesvirus which latently infects B lymphocytes, resulting in concomitant growth transformation of the infected cells. During viral latency, only a limited number of viral genes are expressed, while an estimated 100 or more viral genes associated with the lytic life cycle are quiescent (5, 12) . Indeed, only four viral promoters have been shown to be transcriptionally active during latency, and all are clustered near the latent origin of replication (oriP) (see reference 48) . The six virally encoded nuclear antigens (EBNAs) present in latently infected lymphocytes are encoded by exons spread over the left-hand 110 kilobases (kb) of the viral genome. However, their transcription is driven from one of two viral promoters located at the left-hand end of the genome (10, 44, 46) . The transcripts that encode the EBNAs all share common 5' exons derived from the major internal repeat (IR1) region and are alternatively spliced to the various 3' coding domains (4, 8, 9, 40, 41, 44, 46, 47) . Two other viral genes expressed during latency encode membrane proteins and are under the control of distinct promoters (20, 30) .
In some EBV-infected cell lines, a fraction of the cells can be induced to enter the viral lytic cycle by treatment with various reagents, including phorbol esters, butyrate, ionophore, and anti-immunoglobulin (6, 28, 34, 51, 55) . Alternatively, the lytic cycle can be induced by superinfection with the appropriate strain of EBV (42) . The P3HR-1 strain of EBV is a particularly effective inducer of latently infected cell lines. This strain of EBV has been shown to contain heterogeneous rearranged viral genomes which are responsible for its enhanced ability to induce the lytic cycle (38) . Heterogeneous rearranged viral DNA has been cloned, and a fragment of this defective genome containing the viral BamHI Z fragment rearranged to a portion of the viral BamHI W fragment can disrupt latency when transfected into latently infected lymphocytes (14) . Further studies have demonstrated that expression of the BZLF1 gene from this * Corresponding author. rearranged fragment is responsible for triggering the viral lytic cycle (13) .
Shortly after induction of the viral lytic cycle, several regions of the viral genome become transcriptionally active. In addition to the BZLF1 gene, expression of two other viral genes, BMLF1 and BRLF1, has been identified ( Fig. 1) (11, 26, 33, 50, 54) . All of these viral genes map within the primary transcription unit of one of the EBNA genes expressed during latency, EBNA1, and are transcribed from the opposite strand (Fig. 1) . Each of these viral genes encodes a protein capable of trans activating other viral promoters (11, 26, 29, 32, 33, 50, 53) . However, when these genes are transfected into latently infected lymphocytes under the control of a strong heterologous promoter, only the product of the BZLF1 gene is able to trigger the viral lytic cycle (11) . Furthermore, it has been shown that in the presence of a protein synthesis inhibitor, cycloheximide or anisomycin, only transcription of BZLF1 and BRLF1 can be induced (7, 49) . The accumulated evidence argues strongly that the initial event in the lytic cascade is activation of BZLF1 transcription.
Several transcripts containing BZLF1 have been identified during induction of the lytic cycle, one initiating from Zp and two others initiating from the promoter for the BRLF1 gene (7, 36) . All three of these transcripts contain the complete BZLF1 gene, which is composed of three exons. The BZLF1 protein (which is also referred to as ZEBRA [25] and EB1 [11] ) is 245 amino acids long, and two regions of it are partially homologous to c-fos (residues 36 to 110 and 153 to 196) (19) . Furthermore, it has been shown that the BZLF1 protein exhibits specific DNA-binding properties and can recognize a site with a consensus AP-1 sequence (19) .
A region of Zp from -226 to -118 has previously been reported to be 12-O-tetradecanoylphorbol-13-acetate (TPA) responsive in HeLa cells (53 
MATERIALS AND METHODS
Cell culture, transfections, and CAT assays. Cells were grown at 37°C in RPMI 1640 medium (GIBCO Laboratories) containing 10% newborn calf serum as previously described (47) . Ramos cells (an EBV-negative Burkitt's lymphoma cell line) were transfected by using DEAE-dextran as previously described (37) but with the following modifications. The cells were spun down at 1,000 x g, washed once with RPMI 1640 medium without serum, and suspended at a concentration of 3.3 x 107/ml in RPMI 1640 without serum. Cells (2 x 107; 0.6 ml) were added to sterile tubes containing 4 ,ug of the relevant plasmid DNA, and DEAE-dextran was added to this to a final concentration of 200 ,g/ml (0.4 ml of 0.5 mg/ml). Cells were incubated for 30 min at 37°C, followed by splitting of each transfection into two cultures containing 10 ml of RPMI 1640 with 10% newborn calf serum with or without 20 ng of TPA per ml. Except as noted otherwise, the culture medium posttransfection also contained 1.25 mg of theophylline per ml.
Cells were harvested at 36 h posttransfection, spun down at 1,000 x g, washed once with phosphate-buffered saline, and suspended in 0.1 ml of 0.25 M Tris chloride (pH 7.5). The cell suspension was then lysed by three rounds of freeze-thawing, and the debris was removed by centrifugation. The chloramphenicol acetyltransferase (CAT) activity of the extract was determined as previously described (23), and the extent of acetylation of chloramphenicol was quantitated by excision of spots from thin-layer chromatography plates, followed by liquid scintillation counting.
Plasmid constructions. The HindIII-BamHI fragment of pSV2CAT containing the cat gene was cloned into the HindIII and XhoI sites of the Bluescript polylinker (BS-CAT). A BamHI-NaeI fragment containing the BZLF1 promoter was then inserted upstream from the cat gene by being cloned into the BamHI and HindIll sites of the Bluescript polylinker (Stratagene). The -221ZpCAT construct was generated by digestion of this plasmid with SphI and BamHI, followed by blunting with T4 DNA polymerase and recircularization. Zp deletions were generated by using exonuclease III and mung bean nuclease as previously described (27) and were characterized by DNA sequencing (45) . Site-directed mutagenesis was performed as previously described (22), (for the mutations introduced, see Fig. 4A ). The -41 ,-globin (-41BGCAT) plasmid was described by Fan and Maniatis (18) . SVpCAT was generated by cloning the FokI (blunted)-HindIII fragment containing the simian virus 40 (SV40) promoter from pSV2CAT (23) into the EcoRV and HindIll sites of BS-CAT. The following doublestranded oligonucleotides, containing XbaI and BamHI sticky ends, were cloned in single and multiple copies into the BamHI and XbaI sites of -41BGCAT and SVpCAT: ZIB, 5'-CTAGCAGCTTATTTTAGACACTTC-3' and 5'-GATCGAAGTGTCTAAAATAAGCTG-3'; ZIC, 5'-CTAG CCTCCTCCTCTTTTAGAAACTAT-3' and 5'-GATCATA GTTTCTAAAAGAGGAGGAGG-3'; ZII, 5 a Plasmids were transfected by using DEAE-dextran, and cultures were incubated for 36 h posttransfection with and without 20 ng of TPA per ml and 1.2 mg of theophylline per ml as indicated. The results are averages of three separate experiments. In all cases, theophylline treatment increased the activity without significantly altering the TPA response. SVp, the enhancerless SV40 early promoter; JUNp (-132/+170CAT [1] ), the promoter of the human c-jun gene; FOSp (FC4 [15] ), the human c-fos promoter.
All subsequent steps were performed on ice or at 4°C. The cells were suspended in 5 volumes of ice-cold buffer A (10 mM HEPES [N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid] [pH 7.9], 1.5 mM MgCl2, 10 mM KCl, 0.5 mM dithiothreitol) and homogenized in a Dounce homogenizer, and the crude nuclear fraction was recovered by centrifugation at 10,000 x g for 10 min. The nuclei were suspended in buffer C (20 Footprinting was performed essentially as previously described (31) . Binding reactions were performed in 10 mM Tris (pH 7.9)-0.5 mM EDTA-0.5 mM dithiothreitol-2.5% glycerol-2% polyvinylethanol with a final salt concentration of 40 mM KCl. Extracts were preincubated with 1 ,ug of poly(dI-dc) in the reaction buffer for 10 min at 4°C. The labeled fragment was then added and incubated at 22°C for 20 min before DNase I digestion. The samples were extracted several times with phenol-chloroform (1: 1), ethanol precipitated, and run on a 6% acrylamide denaturing gel.
For competition studies, the following oligonucleotides were used: RI, 5'-AATTGAGGCTCGGTTATTTTGGTTCC T-3' and 5'-AATTAGGAACCAAAATAACCGAGCCTC-3'; RII, 5'-AATTGCCCCATGTGATGGTCAGGG-3' and 5'-AATTCCCTGACCATCACATGGGGC-3'. The ZIB and ZIT oligonucleotides used for competition studies are those described above for cloning into -41BGCAT and SVpCAT plasmids.
RESULTS
The BZLF1 promoter (Zp) is TPA inducible in the absence of other EBV antigens. In tissue culture, the viral lytic cycle can be induced in various EBV-infected cell lines by treatment with several different reagents, including phorbol esters, butyrate, ionophore, and anti-immunoglobulin. The phorbol ester TPA is the most widely used agent for production of virus from inducible cell lines and was chosen to begin an analysis of the initial events involved in the lytic cascade. For these studies, a region of Zp from -221 to + 12 bp was cloned upstream of the bacterial gene that encodes CAT (-221ZpCAT). -221ZpCAT was assayed for activity in a series of EBV-negative and EBV-positive B-cell lines in the absence or presence of 20 ng of TPA per ml (data not shown). Although TPA-inducible activity was detected in EBV-positive cell lines, of the EBV-negative cell lines tested (BL41, BJAB, and Ramos), only the BL cell line Ramos showed detectable activity (Table 1) . These experiments suggested that other EBV factors are important for activation of Zp (21). However, to assess the response of Zp to TPA directly, it was necessary to study this promoter in the absence of other viral gene products through which TPA inducibility could be mediated.
As will be reported elsewhere in detail (unpublished data), treatment of various cell lines with theophylline posttransfection caused a general enhancement in detectable CAT activity. It has been previously reported that theophylline treatment induces endogenous expression of the differentiation-associated CR2 receptor (35) . We initially tested this reagent to differentiate uninfected BL-cell lines to a state more closely approximating that of EBV-infected B lymphocytes, a state which may be necessary for efficient activation of Zp. Theophylline has been reported to be a phosphodiesterase inhibitor and to increase cyclic AMP (cAMP) levels. As shown below, the BZLF1 promoter contains an element (ZII) which is homologous to a cyclic AMP response element binding protein (CREB) site. Therefore, this reagent might activate BZLF1 expression via the ZIT domain.
Theophylline treatment increased the TPA-induced activity of -221ZpCAT circa 10-fold in Ramos cells (Table 1) . However, this effect is not specific for the -221ZpCAT plasmid. Theophylline treatment of Ramos cells also produced approximately a 10-fold increase in CAT activity for several other promoter-cat constructs. We also tested several other cell lines with a larger series of promoter-cat constructs and found similar results (data not shown). Furthermore, as discussed below, we also found that the activity of the -221ZpCAT construct was not responsive to 8-bromo-cAMP or dibutyrl-cAMP, suggesting that elevated cAMP levels do not affect the activity of -221ZpCAT. Therefore, the data indicate that the elevated levels of CAT activity in theophylline-treated cells is elicited via a general mechanism. However, we do not rule out the possibility that theophylline may in some way activate Zp. We are currently testing whether theophylline exerts its effect by increasing the stability of cat mRNA.
As shown for several examples in Table 1 (Fig. 3A) revealed that four of these regions have significant homology to each other (ZI domains; an alignment of these domains is shown in Fig. 3B ). Each repeat contains an A+T-rich sequence juxtaposed to a region with a more complex sequence. The footprint for each repeat contains a characteristic DNase I-sensitive site which maps between the left-hand A+T-rich sequence and the right-hand sequence (see the minus strand for ZIA, ZIB, and ZIC and the plus strand for ZID in Fig. 2 (Fig. 4A) . DNase I footprinting analysis of the promoter for the EBV BRLF1 gene, which has also been shown to be expressed very early in the onset of the viral lytic cycle (7, 49) , revealed a domain, RI, which is partially homologous to the ZI repeats in Zp (Fig. 3B) See Fig. 4 for the corresponding footprint sequence and type I repeat alignment. competed for factors binding to the ZI domains, although slightly less efficiently (Fig. 4A) . Conversely, the ZIB oligonucleotide competed for binding of factors to the RI domain (Fig. 4B) .
To rule out the possibility that the loss of binding of nuclear factors to the other ZI domains by competition with the ZIB oligonucleotide was due merely to loss of cooperative interactions between factors bound at the other ZI domains and those bound to the ZIB domain, competition assays were performed with Zp deletions (Fig. 4C) . The -159Zp deletion, in which the ZIA and ZIB domains are deleted, had no effect on protection of the ZIC or ZID domain by Ramos nuclear extract, and the ZIB oligonucleotide retained its ability to compete for factors that bind to both of these domains. Furthermore, deletion of the ZIC domain (-129Zp) had no effect on binding or competition at the ZID domain. We did not test whether competition for binding to ZIA is independent of the ZIB domain because of their close proximity. However, it appeared that binding of factors to the ZI elements was largely independent, and it is likely that common factors bind to these domains.
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The ZI elements are involved in the TPA inducibility of Zp. To assay for the function of the binding domains described above, a series of deletion mutants were constructed. These mutants were transfected into the Ramos cell line and cultured either with or without TPA (Fig. 5) . A plot of TPA inducibility as a function of the extent of deletion suggests the presence of multiple TPA response elements (Fig. 6) . Deletion of the ZIA and ZIB domains (-159Zp) decreased the TPA inducibility from 20-fold to 9.1-fold. Further deletions which excised the ZIC and ZID domains resulted in only slight decreases in TPA inducibility.
To assess the role of the ZI domains more precisely, site-directed mutagenesis of the A+T-rich sequence in the ZIA and ZIB domains (MIA/B) or in the ZIC domain (MIC) was performed (Fig. 3A) . Both of these mutations resulted in a decrease in TPA inducibility (Fig. 5 and 6 ). The loss of TPA inducibility observed with MIA/B was approximately equivalent to that of its counterpart deletion mutant, -159Zp, in which the ZIA and ZIB domains are deleted. In contrast, the loss of TPA inducibility observed with the MIC-mutant was greater than the loss observed by deletion of the sequence from -159 to -129 bp (which contains the ZIC domain) (Fig. 6) , suggesting that the ZIC domain has a greater impact in the context of the upstream ZIA and ZIB domains. These results indicate that the A+T-rich sequences are essential for the TPA inducibility conferred by this region of Zp.
To assay the TPA inducibility of the ZI domains directly, single or multiple copies of the ZIB and ZIC domains were cloned upstream of the ,B-globin promoter (-41BGCAT) (Fig. 7) . One copy of either the ZIB or ZIC oligonucleotide was sufficient to confer TPA inducibility on the ,-globin promoter. Cloning of three copies of the ZIB domain upstream of the ,-globin promoter resulted in increased TPA inducibility compared with the -41BGCAT plasmid containing a single copy of the ZIB oligonucleotide. Notably, both the ZIB and ZIC oligonucleotides appeared to repress the activity of the P-globin promoter in the absence of TPA. The most dramatic repression was obtained with one copy of the ZIC oligonucleotide, which resulted in 53% reduction of promoter activity.
The repression of promoter activity conferred by the upstream ZI domains was more pronounced when a promoter fragment containing ZIA, ZIB, and ZIC was cloned upstream of the enhancerless SV40 promoter [ Table 2 ; (-221/-129)SVp]. This construct, which leaves the ZIA, ZIB, and ZIC elements in their wild-type configuration, showed 6.4-fold TPA inducibility. However, the predominant effect of adding this fragment upstream from the SV40 promoter was repression of promoter activity in the absence of TPA, an effect which was reversed with TPA treatment. This effect was partially mimicked by cloning three copies of the ZIB domain upstream of SVp (Table 2 ). In contrast, cloning of a fragment of Zp containing the sequences from -129 to -69 bp (containing ZID but not ZII) upstream of SVp exhibited no repressive effect and little TPA inducibility. Although this fragment contains the ZID domain, it also contains approximately 30 bp of upstream sequences which have not been rigorously characterized. Therefore, we do not know whether ZID is not responsive to TPA or whether the apparent lack of TPA responsiveness of this fragment is due to possible negative elements which might mask ZID TPA inducibility. This question requires further investigation.
The ZHI domain is a TPA response element. The deletion analysis shown in Figure 8 indicates that the ZIT domain is also involved in the TPA inducibility of Zp. Comparison of the TPA inducibility of the -85Zp versus -65Zp constructs showed nearly a threefold loss of TPA inducibility. Moreover, when ZIl was mutated by site-directed mutagenesis (Mll), the TPA inducibility of the promoter was reduced from 20-to 3.7-fold ( Fig. 5 and 6 ). We also tested the TPA inducibility of the ZIl domain by cloning it upstream from the P-globin promoter (Fig. 7) . Unlike the ZI elements, the ZIl domain does not act as a repressor in the absence of TPA in this system. Instead, the ZIl domain enhanced basal-level expression 4.0-fold, and addition of TPA resulted in a 2.7-fold increase in activity.
The ZIT domain has a core octanucleotide sequence, 5'-TGACATCA-3', which contains a palindromic sequence found in both the consensus heptanucleotide AP-1 recognition sequence (2) and the octanucleotide CREB recognition sequence (39) (AP-1, TGA-TCA; CREB, TGA--TCA). The palindrome in the AP-1-binding site is separated by only one nucleotide, whereas the CREB palindrome is separated by two nucleotides, although exceptions do exist. The c-jun promoter, for example, contains an octanucleotide sequence VOL. 64, 1990 on Competition by the ZIB oligonucleotide for binding of nuclear factors to ZI domains using Zp deletions. Labeled fragments were generated from the corresponding deletion mutants. Zp fragments were labeled at the HindlIl site between the cat gene and the promoter fragment (sense strand). Promoter fragments were then excised by digestion the Sacl site located in the Bluescript polylinker. Each fragment contains the sequences extending to the indicated base in Zp plus an additional 6 bp of the double-stranded polylinker sequence. An 80-,ug sample of Ramos cell nuclear extract and an 80-ng sample of the ZIB oligonucleotide were used. N.E., No extract; N.C., no competitor.
which is responsive to TPA and has been shown to be a high-affinity AP-1-binding site (1) . Moreover, the c-jun promoter is not responsive to dibutyryl-cAMP in HeLa cells (P. (Fig. 3C). (ii) In our study, the BZLF1 promoter was not responsive to 8-bromo-cAMP or dibutyryl-cAMP in the Ramos cell line (data not shown). (iii) The ZII domain is responsive to TPA. We therefore examined whether a complex of c-jun and c-fos could bind to the ZIl domain (Fig. 9) . DNase I footprinting with extracts from baculovirus-infected insect cells (extracts were prepared either from cells infected with the wild-type virus or from cells infected with a recombinant virus encoding the rat c-fos or c-jun gene) demonstrated binding of the c-jun-c-fos complex to the ZII domain.
Consistent with the results obtained with HeLa cell extracts (1), the c-jun AP-1 site was protected by extracts from the B-cell line Ramos (Fig. 8 ). An oligonucleotide containing the ZII domain was able to compete for binding of transcription factors to the c-jun AP-1 site (Fig. 8) . As a control, the ZlI oligonucleotide was used to compete for binding of factors to the ZIT site in the Zp promoter at the same oligonucleotide concentrations. The ZII oligonucleotide competed for factor binding to either site with approximately equal efficiency. On the basis of these data, we conclude that the ZII domain may be functionally related to the AP-1 site in the c-jun promoter.
Interestingly, although the ZIB oligonucleotide which was used as a control for the above-described experiment did not compete for factors binding to the c-jun AP-1 site, it did compete for factors binding to a site adjacent to it (Fig. 8) .
Juxtaposed to the AP-1 site is a sequence homologous to the type I domain A+T-rich sequence (Fig. 3C) . Unfortunately, this A+T-rich sequence in the c-jun promoter is recalcitrant to DNase I digestion. However, the sequence immediately adjacent to the A+T-rich domain is sensitive to digestion and is protected in the presence of Ramos cell nuclear extract (Fig. 8) . The ability of the ZIB oligonucleotide to compete effectively for binding to this region suggests that the A+T-rich sequences are contained within this domain. (Fig. 3A) . CAT assays were quantitated by liquid scintillation, and the activities are expressed relative to the activity of -221ZpCAT (with TPA). The values given represent averages of three independent experiments.
Notably, a similar configuration of a type I domain juxtaposed to an AP-1-like site is present in Zp (the ZID and ZIT domains).
DISCUSSION
Consistent with its proposed role in the lytic switch, the promoter for the BZLF1 gene can be induced by TPA, a reagent which is known to activate the EBV lytic cycle. Moreover, this activation can take place without other viral gene products. DNase I footprint analysis of Zp identified multiple domains for cellular transcription factors. Four of these domains appear to bind related protein complexes, since complex formation at these sites can be competed for successfully with an oligonucleotide containing only one of these domains (ZIB). In addition, several lines of evidence indicate that these domains function as TPA response elements. We further analyzed binding of factors to the ZI domains by gel retardation assays using oligonucleotides containing individual ZI domains (data not shown). The results of this study indicate that multiple transcription factors can bind to each repeat. Further dissection of these domains will be required to assess the importance of specific regions within the ZI repeats. However, the A+T-rich sequences appear to be important for their function, since mutagenesis of the A+T-rich core of ZIA-ZIB or ZIC largely abrogates the TPA inducibility attributable to those regions of Zp from functional analysis of Zp deletions.
Potentially, an important function of the ZI repeats is their behavior as silencers which exhibit a TPA-inducible enhancer function. This may be a mechanism which helps ensure quiescence of Zp and thereby EBV latency in the absence of the proper activation signals. TPA-responsive elements with sequences similar to the ZI elements reported here have not been previously described. However, an element similar to the A+T-rich domains described here has been reported in the enhancers of two different muscle genes (17, 24, 52) and in the promoter of the rat myosin light-chain TPA inducibility of ZI and ZIl oligonucleotides cloned upstream of the 3-globin promoter. CAT assays were quantitated by liquid scintillation, and the fold TPA induction is indicated. These results were reproduced several times, and this reflects a typical assay.
promoter (3) . In the muscle creatine kinase gene, an upstream enhancer contains a single copy of an element with the core sequence TTATTTTTA. This element has been shown to bind two different factors, MEF-2 and MBF-1. Synthesis of the former is rapidly induced upon differentiation of myoblasts to myotubes, while the latter is found in myoblasts and is down regulated during differentiation (24) .
Zp also contains a distinct TPA response element located within the ZlI domain. The ZlI domain contains an octanucleotide core sequence (TGACATCA) homologous to the c-jun AP-1-binding site (1) . It was shown that c-jun and c-fos made from baculovirus-infected insect cell extracts can bind to the ZlI domain. Binding competition studies demonstrated that a factor(s) found in B cells bound with approximately equal affinity to the ZlI domain and the AP-1 site found in the c-jun promoter, suggesting more directly that in B lymphocytes these domains are functionally related. However, c-jun did not exhibit the ability to transactivate Zp when Ramos cells were cotransfected with ZpCAT and a c-jun expression vector (data not shown). In an analogous experiment performed with a c-jun-cat construct (which contains the c-jun AP-1 site), the c-jun promoter was not transactivated by the c-jun-encoded protein (data not shown). The latter is in contrast to results obtained with HeLa cells (1) , which we were able to reproduce. It is possible that the TPA inducibility of the ZlI domain in the Ramos cell line is due to a different member(s) of the AP-1 family and that c-jun is not active in these cells or at least not active in conjunction with either the ZII or c-jun AP-1 domain.
A recent report (53) investigating Zp activity in HeLa cells mapped TPA inducibility to the region containing ZIA, ZIB, and ZIC. However, those investigators detected no TPA inducibility mapping to the region containing ZII. The reason for this difference is not clear, although it is likely to reflect cell type-specific differences. We considered the possibility that theophylline treatment activated ZII to be responsive to TPA. However, the effect of deletion of these domains in the EBV-positive Burkitt's lymphoma cell line Cl-13 in the absence of theophylline mimics the results presented here (data not shown).
We have shown that the TPA response elements in Zp appear to fall into two groups: the ZI repeats and the ZlI domain. Since different transcription factors interact with these distinct response elements, it is likely that TPA response is mediated via two different pathways. The nearly J. VIROL. 
